Table 4A.
Univariable and multivariable analysis of predictors of mortality in the entire cohort.
| Univariable | Multivariable | |||||||
|---|---|---|---|---|---|---|---|---|
| p value | HR | 95% CI | p value | HR | 95% CI | |||
| Lower | Upper | Lower | Upper | |||||
| Sex | ||||||||
| Female | - | - | - | - | ||||
| Male | 0.336 | 1.191 | 0.835 | 1.698 | ||||
| Age | <0.001 | 1.029 | 1.014 | 1.045 | <0.001 | 1.036 | 1.019 | 1.052 |
| Status malignancy at COVID-19 diagnosis | ||||||||
| Controlled malignancy | - | - | - | - | - | - | - | - |
| Stable malignancy | 0.893 | 1.036 | 0.622 | 1.724 | 0.830 | 0.945 | 0.561 | 1.590 |
| Active malignancy | 0.003 | 1.798 | 1.222 | 2.646 | <0.001 | 2.215 | 1.501 | 3.267 |
| Malignancy | ||||||||
| Chronic lymphoid leukemia | - | - | - | - | ||||
| Non-Hodgkin lymphoma | 0.330 | 1.185 | 0.842 | 1.669 | ||||
| COVID-19 infection | ||||||||
| Asymtomatic | - | - | - | - | - | - | - | - |
| Mild | 0.899 | 1.056 | 0.458 | 2.435 | 0.718 | 1.176 | 0.488 | 2.834 |
| Severe | 0.043 | 1.948 | 1.021 | 3.714 | 0.017 | 2.270 | 1.156 | 4.460 |
| Critical | <0.001 | 4.563 | 2.376 | 8.764 | <0.001 | 5.751 | 2.875 | 11.506 |
| Chronic cardiopathy | 0.025 | 1.491 | 1.052 | 2.113 | 0.775 | 1.056 | 0.726 | 1.536 |
| Chronic pulmonary disease | 0.393 | 1.188 | 0.800 | 1.763 | ||||
| Diabetes mellitus | 0.615 | 1.116 | 0.727 | 1.715 | ||||
| Liver disease | 0.837 | 1.090 | 0.480 | 2.474 | ||||
| Obesity | 0.820 | 0.920 | 0.450 | 1.882 | ||||
| Renal impairment | <0.001 | 2.705 | 1.577 | 4.638 | 0.086 | 1.667 | 0.929 | 2.992 |
| Smoking history | 0.482 | 1.190 | 0.732 | 1.936 | ||||
| Neutrophils | ||||||||
| ≤ 500 | - | - | - | - | ||||
| 501 - 999 | 0.987 | 1.008 | 0.398 | 2.555 | ||||
| ≥ 1000 | 0.107 | 0.553 | 0.269 | 1.137 | ||||
| Lymphocytes | ||||||||
| ≤ 200 | - | - | - | - | ||||
| 201 - 499 | 0.874 | 1.067 | 0.479 | 2.375 | ||||
| ≥ 500 | 0.918 | 0.965 | 0.487 | 1.913 | ||||
| Time last chemotherapy | ||||||||
| In the last month | - | - | - | - | ||||
| In the last 3 months | 0.975 | 1.008 | 0.616 | 1.649 | ||||
| >3 months before COVID-19 | 0.313 | 0.767 | 0.458 | 1.284 | ||||
| Chemotherapy lines before COVID-19 | ||||||||
| 1 | - | - | - | - | ||||
| 2 | 0.062 | 1.516 | 0.979 | 2.347 | ||||
| 3 | 0.158 | 1.441 | 0.868 | 2.395 | ||||
| 4 | 0.043 | 1.886 | 1.020 | 3.489 | ||||
| >4 | 0.061 | 1.867 | 0.972 | 3.584 | ||||
| SARS-CoV-2 | ||||||||
| α mutation (Alpha) | - | - | - | - | ||||
| β mutation (Beta) | 0.837 | 1.121 | 0.376 | 3.343 | ||||
| Wild type | 0.953 | 1.032 | 0.367 | 2.902 | ||||
| Not tested/Unknown | 0.880 | 1.065 | 0.468 | 2.426 | ||||
| Vaccine doses before COVID-19 | ||||||||
| No vaccination | – | – | – | – | ||||
| One dose | 0.972 | 1.015 | 0.445 | 2.312 | ||||
| Two doses | 0.829 | 0.940 | 0.537 | 1.646 | ||||
| Three doses | 0.867 | 0.845 | 0.118 | 6.068 | ||||
| Time last vaccination to COVID-19 | ||||||||
| ≤14 days before COVID-19 | - | - | - | - | ||||
| >14 days before COVID-19 | 0.732 | 1.190 | 0.439 | 3.222 | ||||
| COVID-19 treatment | ||||||||
| No treatment | - | - | - | - | ||||
| Antivirals +/- corticosteroids +/- plasma | 0.292 | 1.752 | 0.617 | 4.974 | ||||
| Monoclonal antibodies +/- corticosteroids +/- plasma | 0.659 | 1.623 | 0.189 | 13.925 | ||||
| Antivirals + monoclonal antibodies +/- corticosteroids +/- plasma | 0.544 | 1.444 | 0.440 | 4.740 | ||||
| Corticosteroids | 0.022 | 3.119 | 1.180 | 8.246 | ||||
| Plasma +/- corticosteroids | 0.632 | 0.591 | 0.069 | 5.063 | ||||
| Unknown | 0.198 | 1.810 | 0.734 | 4.460 | ||||